InvestorsHub Logo
Followers 24
Posts 2317
Boards Moderated 0
Alias Born 12/21/2020

Re: None

Friday, 07/14/2023 7:50:51 AM

Friday, July 14, 2023 7:50:51 AM

Post# of 27
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs

Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation

[color=red] Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026

WHAT IS THE SHARES STRUCTURE
[t][color=red][/color][/t][/color]
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FREQ News